Skip to main content

Table 4 Clinical treatment and short-term outcomes in AECOPD patients

From: Aspergillus fumigatus during COPD exacerbation: a pair-matched retrospective study

  Aspergillus colonization, n = 23 Control, n = 69 p value
Admitted in ICU 4 (17.4%) 11 (15.9%) 1.000
Machined ventilation 3 (13.0%) 9 (13.0%) 0.906
Antibiotics 21 (95.5%) 66 (95.7%) 1.000
 More than 1 class 52.2% 21.7% 0.006
 Duration of treatment (days) 13 ± 5 10 ± 4 0.003
Corticosteroid use 17 (77.3%) 42 (60.9%) 0.204
 Systemic only 0 2 (2.90%) 1.000
 Inhalation only 8 (34.8%) 20 (29.0%) 0.601
Dose of usage
 Budesonide (inhaled,≥40 mg) 30.4% 5.8% 0.002
 Methylprednisolone (iv,≥120 mg) 39.1% 31.9% 0.524
Bronchodilators (aerosol inhalation) 21 (91.3%) 57 (82.6%) 0.505
 Ipratropium Bromide (mg) 16.3 ± 11.6 14.8 ± 8.2 0.631
 Salbutamol (mg) 115 ± 98 83 ± 53 0.308
Remission time (days) 11 ± 4 7 ± 4 0.001
Duration of hospitalization (days) 15 ± 5 12 ± 4 0.011
  1. Italicized p-values are statistically significant, ie. p < 0.05